AmyriAD Therapeutics has acquired the AD04 Alzheimer’s disease program and related assets from ADvantage Therapeutics, expanding its clinical-stage pipeline focused on cognitive decline.
The transaction gives AmyriAD worldwide rights to AD04, including associated intellectual property, clinical data and regulatory assets.
AD04 is a Phase 2b-ready investigational treatment being developed for mild Alzheimer’s disease.
The drug is administered subcutaneously and is based on a proprietary dosage and formulation of aluminum hydroxide hydrogel.
AmyriAD said AD04’s proposed mechanism involves peripheral inflammation that ultimately supports inflammation resolution in the brain and removal of waste material including lipid microdroplets.
The clinical rationale for the program emerged from AFF006, a 332-patient Phase 2 Alzheimer’s vaccine study in which AD04 served as a control treatment.
Exploratory post hoc analyses of patients who received AD04 showed signals of slower cognitive decline and reduced hippocampal volume loss.
AmyriAD plans to move the program into Phase 2b development to prospectively evaluate its safety and efficacy in patients with mild Alzheimer’s disease.
AD04 has already received an Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway.
Jeffrey B. Madden and members of ADvantage’s clinical and scientific team will remain involved as advisors to support continuity as the program advances.
AD04 joins a broader AmyriAD cognition pipeline that includes Ismidenon and RL-007.
Ismidenon is AmyriAD’s lead program and is being developed as an oral add-on symptomatic treatment for cognitive impairment in moderate Alzheimer’s disease.
The drug targets presynaptic T-type calcium channels to increase acetylcholine release and has already been studied in more than 500 patients.
AmyriAD is also developing RL-007, or Inidascamine, an oral small molecule targeting multiple signaling pathways involved in cognition.
KEY QUOTES:
“Cognitive decline threatens people’s independence, relationships and daily lives. Addressing it requires more treatment options across different biological mechanisms and stages of disease. Following our acquisition of Recognify Life Sciences, AD04 further expands our cognition pipeline alongside lead program Ismidenon. We are building this portfolio with a clear purpose: helping people preserve the abilities that make life their own.”
K. Ranga Rama Krishnan, Chairman Of The Board And CEO Of AmyriAD Therapeutics
“AD04’s clinical findings provide a compelling foundation for its continued development in mild Alzheimer’s disease. I’m excited to combine our experience with AD04 and AmyriAD’s expertise in cognition as we advance toward Phase 2b, building on the program’s Innovation Passport under the United Kingdom’s Innovative Licensing and Access Pathway (ILAP).”
Jeffrey B. Madden, Chief Executive Officer Of ADvantage Therapeutics

